NCT00390624

Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol

Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Rocky Mountain Cancer Centers · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to combine Urodilatin (ANP analogue), which will increase glomerular filtration rate (GFR), and mannitol, which will increase the rate of urinary flow and solute excretion. We intend to treat twenty consecutive allogeneic bone marrow transplant patients in a phase II study comparing results with historical controls. We hypothesize that the incidence of renal dysfunction, ARF and thus mortality in allogeneic bone marrow transplantation can be significantly reduced by the use of protective agents Urodilatin and mannitol. We feel that this combination is best administered prior to and during the first two weeks of treatment when patients encounter immunosuppressive agents and the onset of early transplantation complications.

Conditions

• Renal Dysfunction
• Acute Renal Failure
• Mortality

Interventions

Type	Name	Description
DRUG	URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)
DRUG	MANNITOL

Timeline

• Start date: 2003-07-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2006-10-20
• Last updated: 2008-06-03

Locations

1 site across 1 country: United States